Divi's Laboratories share news and announcements
NSE: DIVISLABBSE: 532488Pharmaceuticals & BiotechnologyLarge Cap
Last close ₹8,950.00down ₹212.00 (2.31%)BSE ₹8,984.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹9,162.00.
52-week range of traded prices to 23 Oct 2026
₹5,647.50Low, 2 Apr 2026₹9,740.00High, 24 Sep 2026
- Next results date: the board meets on 7 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,37,594 Cr50th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 1 Aug 2026
- 81.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 27 May 2026
- 14.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 1 Aug 2026
- 18.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 1 Aug 2026
- 20.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 27 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,20,26160.6% delivered
Divi's Laboratories results
109 filed, newest first. Page 3 of 3.
Jan 2008
28 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 28422 lacs for quarter ending on 31-DEC-2007 against Rs. 14962 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 10066 lacs for the quarter ending on 31-DEC-2007 against Rs. 3273 lacs for the quarter ending on 31-DEC-2006.
Oct 2007
27 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 47056 lacs for half year ending on 30-SEP-2007 against Rs. 32241.27 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 15586 lacs for the half year ending on 30-SEP-2007 against Rs. 5553.91 lacs for the half year ending on 30-SEP-2006.27 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 24384 lacs for quarter ending on 30-SEP-2007 against Rs. 16172.15 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 9097 lacs for the quarter ending on 30-SEP-2007 against Rs. 2990.5 lacs for the quarter ending on 30-SEP-2006.27 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 24251 lacs for quarter ending on 30-SEP-2007 against Rs. 16136.61 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 9125 lacs for the quarter ending on 30-SEP-2007 against Rs. 3128.22 lacs for the quarter ending on 30-SEP-2006.
Jul 2007
30 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 22672 lacs for quarter ending on 30-JUN-2007 against Rs. 16069.12 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 6490 lacs for the quarter ending on 30-JUN-2007 against Rs. 2563.41 lacs for the quarter ending on 30-JUN-2006.30 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 22807 lacs for quarter ending on 30-JUN-2007 against Rs. 16083.9 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 6728 lacs for the quarter ending on 30-JUN-2007 against Rs. 2674.5 lacs for the quarter ending on 30-JUN-2006.10 Jul · Results
Report issued by Mr.V.Bhasakara Rao, Company Secretary in Practice, Scrutinizer for the Postal Ballot conducted in pursuance of Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution through Postal Ballot) Rules 2001, in respect of (i) sub division of the equity shares of Rs.10/- each of the Company into 5 (Five) shares of Rs.2/- each and (ii) reappointment and enhancement of remuneration payable to Dr P Gundu Rao, Director (R&D) of the Company. Basing on the report submitted by the Scrutinizer, Mr. N V Ramana, Executive Director has declared on July 09, 2007 that the resolutions are passed with requisite majority. The company has further informed the Exchange that the members of the company have approved the (i) sub division of the Equity shares of the Company to Rs.2/- per share from the existing Face Value of Rs.10/- per share and (ii) reappointment and enhancement of remuneration payable to Dr P Gundu Rao, Director (R&D) of the Company. The details of the results of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
21 May · Results
Report issued by Mr.V.Bhasakara Rao, Company Secretary in Practice, Scrutinizer for the Postal Ballot conducted in pursuance of Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution through Postal Ballot) Rules 2001, in respect of four Ordinary Resolutions to increase the remuneration payable to Whole-time Directors of the company in accordance with the provisions of Sections 198, 269, 309, 310, 314 and other applicable provisions, if any read along with Schedule XIII of the Companies Act, 1956. Basing on the report submitted by the Scrutinizer, Dr P Gundu Rao, Director (R & D) has declared on May 19, 2007 that the resolutions are passed with requisite majority. The company has further informed the Exchange that the members of the company have approved increase of remuneration payable to whole-time Directors of the company, in accordance with the provisions of Sections 198, 269, 309, 310, 314 and other applicable provisions, if any read along with schedule XIII of the Companies Act, 1956. The details of the results of the Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
17 Apr · Results
The Audited Financial Results of the Company for the entire financial year 2006-2007 shall be considered and published by the Company within a period of three months from the end of the financial year, i.e. on or before 30th June 2007. Hence the Company is not considering the un-audited financial results for the last quarter of the financial year ended on 31st March 2007